Petros Pharmaceuticals, Inc. (PTPI)
NASDAQ: PTPI · Real-Time Price · USD
0.270
+0.013 (5.02%)
At close: Nov 22, 2024, 4:00 PM
0.255
-0.015 (-5.52%)
After-hours: Nov 22, 2024, 6:29 PM EST
Petros Pharmaceuticals Stock Forecast
PTPI's stock price has decreased by -79.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for PTPI stock has a target of 4.00, which predicts an increase of 1,382.03% from the current stock price of 0.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 8, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for PTPI is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 |
---|---|
Strong Buy | 1 |
Buy | 0 |
Hold | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +1,382.03% | Dec 8, 2023 |
Financial Forecast
Revenue This Year
5.54M
from 5.82M
Decreased by -4.80%
Revenue Next Year
5.59M
from 5.54M
Increased by 0.76%
EPS This Year
-2.17
from -6.35
EPS Next Year
-1.11
from -2.17
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 5.7M | 5.7M | 5.7M | ||
Avg | 5.5M | 5.6M | 5.6M | ||
Low | 5.3M | 5.4M | 5.3M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.0% | 3.7% | 2.5% | ||
Avg | -4.8% | 0.8% | -0.4% | ||
Low | -8.5% | -3.2% | -4.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.24 | -1.14 | -1.16 | ||
Avg | -2.17 | -1.11 | -1.12 | ||
Low | -2.09 | -1.07 | -1.08 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.